Treatment Trials

Search clinical trials by condition, location and status

Free to JoinExpert SupportLatest Treatments

Filter & Search

Clinical Trial Results

Showing 1-2 of 2 trials for Solid-organ-transplant-complications
Recruiting

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus (EBV)-Associated Diseases

California · Los Angeles, CA

The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.

Epstein-Barr Virus (EBV)-Associated DiseasesEBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
Talk to a Navigator
Recruiting

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

California · Los Angeles, CA

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative DisordersAllogeneic Hematopoietic Cell Transplant
Talk to a Navigator